Notification: The cat. codes have been changed from bimab-bgalhcd3 and bimab-bgalhcd3-05 to bimab-bgcd3-01 and bimab-bgcd3-05.

Anti-βGal-hCD3 binds to hCD3 on T cells but not to hCD19 on B cells

Monoclonal scFv antibody against β-galactosidase and human CD3; Negative control

Anti-βGal-hCD3 is a bispecific antibody that binds to two sites: E. coli β-galactosidase (β-Gal)and hCD3, part of the T cell receptor. It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, alike Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].

References:

1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.

Clear allRefined by

Products1

1 Search results: BIMAB-BGCD3-01